Clinical presentation of inhibitor development in non-severe hemophilia A: half of patients have high titer inhibitors and present with bleeding complications

Author(s):
Eckhardt, C.L.; Loomans, J.I.; Velzen, A.S. van; Peters, M.; Astermark, J.; Brons, P.P.; Castaman, G.; Cnossen, M.H.; Dors, N.; Escuriola-Ettingshausen, C.; Hamulyak, K.; Hart, D.P.; Hay, C.R.M.; Haya, S.; Heerde, W.L. van; Hermans, C.; Holmstrom, M.; Jimenez-Yuste, V.; Keenan, R.D.; Klamroth, R.; Laros-Gorkom, B.A.P. van; Leebeek, F.W.G.; Liesner, R.; Makipernaa, A.; Male, C.; Mauser-Bunschoten, E.; Mazzucconi, M.G.; Mcrae, S.; Meijer, K.; Mitchell, M.; Morfini, M.; Nijziel, M.; Oldenburg, J.; Peerlinck, K.; Petrini, P.; Platokouki, H.; Rangarajan, S.; Reitter-Pfoertner, S.E.; Santagostino, E.; Schinco, P.; Smiers, F.J.; Siegmund, B.; Tagliaferri, A.; Yee, T.T.; Kamphuisen, P.W.; Bom, J.G. van der (0000-0001-5251-0342); Fijnvandraat, K.; Insight Study Grp
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-05-31
Language
English
Is part of
Haemophilia (2014), Vol. 20, p. 55-55
hdl
1887/104229